{"groups":[{"description":"\\- Participants will receive Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone on a 28-day cycle.\n\n* Oral:\n\n  * Ixazomib given weekly on days 1, 8, 15\n  * Dexamethasone given weekly during cycle\n* Infused:\n\n  * Nivolumab given once per cycle\n  * Cyclophosphamide given on days 1, 8, 15 during cycle\n\nNivolumab: Given intravenously once per cycle\n\nIxazomib: Given orally on days 1, 8, 15.\n\nDexamethasone: Given orally on days 1, 8, 15, 22\n\nCyclophosphamide: Given intravenously on days 1, 8, 15.","id":"FG000","title":"Nivolumab and Ixazomib"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}